Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection

Autor: Robert Rzepko, Anna Lowczak, Jakub Pałucki, Karolina Osowiecka, Lidka Glinka, Agnieszka Kolasińska-Ćwikła, Anna Doboszyńska, Jarosław B. Ćwikła
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Journal of Clinical Medicine
Volume 9
Issue 5
Journal of Clinical Medicine, Vol 9, Iss 1370, p 1370 (2020)
ISSN: 2077-0383
DOI: 10.3390/jcm9051370
Popis: Large-cell neuroendocrine carcinoma (LCNEC) is a rare malignancy with poor prognosis. The rationale of the study was to determine the survival of LCNEC patients in I&ndash
IIIA clinical stages who underwent resection. A total of 53 LCNEC (89%) and combined LCNEC (11%) patients in stages I&ndash
IIIA who underwent surgery with radical intent between 2002&ndash
2018 were included in the current study. Overall survival (OS) and time to recurrence (TTR) were estimated. Uni- and multivariable analyses were conducted using Cox-regression model. Patients were treated with surgery alone (51%), surgery with radiochemotherapy (4%), with radiotherapy (2%), with adjuvant chemotherapy (41%), or with neoadjuvant chemotherapy (2%). The median (95% Confidence Interval (CI)) OS and TTR was 52 months (20.1&ndash
102.1 months) and 20 months (7.0&ndash
75.6 months), respectively. Patients treated in clinical stage I showed better OS than patients in stages II&ndash
IIIA (p = 0.008). Patients with R0 resection margin (negative margin, no tumor at the margin) and without lymph node metastasis had significantly better TTR. In the multivariate analysis, age was an independent factor influencing OS. Recurrence within 1 year was noted in more than half cases of LCNEC. R0 resection margin and N0 status (no lymph node metastasis) were factors improving TTR. Age >
64 years was observed as a main independent factor influencing OS.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje